Dec 22nd, 2020
Starpharma today announced that it has received all necessary approvals to commence its clinical study for VIRALEZE™. The study will commence enrolment of healthy volunteers in Perth in early January 2021 and is expected to be completed in Q1 2021. This study is being undertaken to support commercialisation activities for VIRALEZE™, and is not a requirement to achieve EU product registration.Read More
Dec 10th, 2020
Starpharma today announced significant commercial and regulatory progress has been made for VIRALEZE™ nasal spray with the EU regulatory dossier more than 90% complete and VIRALEZE™ now on track to be registered, and ready for market in Q1 CY2021. This timing is earlier than previously announced.Read More
Nov 20th, 2020
Seeking Alpha, a financial market portal featured a piece on Starpharma’s latest update on its VIRALEZE™ COVID-19 nasal spray. The article noted the potential of the spray and Starpharma’s latest regulatory developments on this front. To read the full article click here.Read More
Nov 19th, 2020
Starpharma today announced it has completed additional testing showing potent antiviral activity of SPL7013 against human respiratory syncytial virus (RSV). RSV is a common and very contagious virus that affects the lungs and airways. RSV is most problematic in the young and the elderly and those with weakened immune systems, or chronic heart and lung disease, including asthma. More than 177,000 adults are hospitalized and 14,000 of them die due to RSV infection in the US annually. RSV is also one of the viruses responsible for the common cold.
Oct 29th, 2020
Starpharma today announced that it has completed its Share Purchase Plan (SPP), raising $3.9 million. The SPP was conducted in conjunction with Starpharma’s recent institutional placement (Placement), which together have raised a total of $48.9 million. The issue of 2.6 million new shares under the SPP will be at $1.50 per share, being equivalent to the Placement share price.
Oct 21st, 2020
The Market Herald reported that Starpharma are to receive a $5.7 million research and development (R&D) tax incentive refund from the Federal Government following the government’s program to support companies taking on R&D that benefits Australia. To watch the full video click here.Read More
Oct 21st, 2020
Starpharma today announced that it has received a $5.7M R&D tax incentive refund which relates to the costs of research and development during the 2020 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including for COVID-19, DEP® and VivaGel® programs.Read More
Oct 20th, 2020
In this issue:
>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray
>> Rapid progress in the DEP® irinotecan phase 2 & preparations underway for clinical combinations
>> DEP® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models
>> VivaGel® BV launched in Central & Eastern Europe and Nordic region
>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication
>> VivaGel® BV has now been approved in 40 countries with further submissions underway
>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray
>> DEP® docetaxel update & patient case study
>> DEP® cabazitaxel update & patient case study
>> Multiple DEP® products showcased at AACR 2020 Annual Meeting
>> New DEP® partnership signed with Chase Sun for anti-infective program
>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center
>> Starpharma creates slow release soluble DEP® remdesivir
>> DEP® partnering, including Antibody Drug Conjugates
>> DEP® lutetium; impressive efficacy in human prostate cancer model
>> Outlook, Annual Report & ESG Report & recent newsRead More
Oct 16th, 2020
Online financial news platform FN Arena recently published an article which highlighted six biotech ASX-listed companies that have recently been viewed positively by analysts. Starpharma was listed as one such company, stating that Bell Potter had emphasized the company’s strong growth potential. To read the full article click hereRead More
Oct 8th, 2020
Starpharma was featured in an article by Stockhead, an online publication that delivers news on ASX-listed small and mid-cap companies. The piece looked at the Federal Government’s decision to abandon plans to reduce R&D tax refund by $1.8B, and will instead add $200M in value to the incentive. The article noted Starpharma received a $4.9M tax refund in December 2019 for R&D associated with the development of its DEP drug delivery system and VivaGel BV women’s health products.
To read the full article click here.
Oct 8th, 2020
On 8 October, Starpharma was included in the SMH’s live market update which reported Allianz Global Investors had upped its stake in Starpharma after buying close to 10 million additional shares. It added that the fund’s position in the company had risen from 5 to 7.1 per cent. To read the full article click hereRead More
Sep 30th, 2020
Starpharma today announced that it has raised A$45 million via a placement to domestic and international institutional, sophisticated and professional investors (“Placement”). Eligible shareholders will also have the opportunity to participate, at the same price, through a Share Purchase Plan (SPP) which is expected to raise approximately A$5 million.Read More
Sep 25th, 2020
Starpharma today announced that the Australia Therapeutic Goods Administration (TGA) has approved an expansion of the marketing authorisation for VivaGel® BV (Fleurstat BVgel) to now include the indication of prevention of recurrent bacterial vaginosis. These expanded claims bring the approved indications for VivaGel® BV (Fleurstat BVgel) in line with those in Europe and Asia.Read More
Starpharma is interviewed by Stockhead to give a company overview and provide an update on its COVID-19 nasal spray
Sep 17th, 2020
Stockhead’s Tim Boreham interviewed Starpharma CEO Jackie Fairley for their Health Kick Podcast. Tim reported that Starpharma has gone from strength to strength following progress on its COVID-19 nasal spray. To hear an overview of the company, and update on current development programs and plans for the year ahead, listen to the full episode hereRead More
Sep 17th, 2020
Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 17 September 2020 (US ET) as part of OTCQX’s Life Sciences Investor Forum.Read More
Sep 14th, 2020
Starpharma today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.Read More
Sep 3rd, 2020
Starpharma today announced the award of $1 million in matched funding by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program to expedite development and commercialisation of its COVID‑19 antiviral nasal spray based on Starpharma’s proprietary dendrimer, SPL7013.
Sep 1st, 2020
Starpharma today announced it has applied its novel DEP® drug delivery technology to create a long‑acting, water soluble version of remdesivir. Remdesivir is an antiviral drug, currently being developed by Gilead to treat COVID-19 and has emergency use authorisation from the US Food and Drug Administration for the treatment of COVID-19 in adults and children hospitalised with severe disease.Read More
Aug 26th, 2020
2GB radios Jim Wilson interviewed Starpharma CEO Dr Jackie Fairley to get an update on how Starpharma is fast-tracking a nasal spray designed to be used as a preventative measure in the fight against COVID-19.
To listen to the full interview click here.Read More
Aug 26th, 2020
Starpharma was featured on ABC’s finance news segment ‘The Kohler Report’, where Alan Kohler highlighted that Starpharma shares had risen 23% following the Company’s update on its SPL7013-based antiviral nasal spray, which has shown to have potent antiviral activity against COVID-19. The update included that Starpharma has commenced confidential commercial discussions with related parties.
To watch the full report, click here.Read More
Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19
Aug 26th, 2020
Starpharma was recently featured in an article by Australian Manufacturing, a leading publication and resource for the manufacturing and industrial sector in Australia. The article noted Starpharma had undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and confirmed to have potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The article also highlightsed SPL has identified a manufacturer and are currently compiling documentation in preparation for regulatory submission.
To read the full article click here.Read More
Aug 25th, 2020
Starpharma today announced progress with development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company’s proprietary antiviral dendrimer, SPL7013.Read More
Aug 17th, 2020
Starpharma today announced that it has signed a new research partnership with leading Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical Co., Ltd. (stock code 300026; Chase Sun), to develop several DEP® nanoparticle formulations for an anti-infective drug. The agreement also provides for the potential to conduct additional DEP® programs, which can be across therapeutic areas beyond anti-infectives.
Jul 30th, 2020
Starpharma today announced that it has commenced its DEP® docetaxel + gemcitabine combination study for patients with advanced cancers, including pancreatic cancer. Recruitment into the study has commenced at the Christie in the UK, with two further sites expected to open in the coming weeks.
Jul 27th, 2020
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the opening of the MD Anderson Cancer Center as a further trial site for the phase 1 trial of AZD0466, AstraZeneca’s first DEP® product.Read More
Jul 9th, 2020
Starpharma today announced the opening of a new trial site for the phase 2 DEP® irinotecan trial, at the Kinghorn Cancer Centre in Sydney. The DEP® irinotecan trial is also being conducted at multiple leading UK cancer centres including The Christie, The Royal Marsden, Newcastle Freeman Hospital, and The Beatson West of Scotland Cancer Centre. The Kinghorn Cancer Centre will also be opened shortly as an additional site for the phase 2 DEP® cabazitaxel trial.
The Age: Starpharma CEO Dr Jackie Fairley on Australia’s need to turn homegrown research into commercial products
Jul 3rd, 2020
The Age interviewed Starpharma CEO Dr Jackie Fairley about how the COVID-19 pandemic could be the much needed catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. Dr Fairley also covered Starpharma’s recent activities in response to the pandemic including, the development of a nasal spray product using the antiviral dendrimer, SPL7013.
To read the full interview click here.Read More
Jul 3rd, 2020
The Age recently interviewed Starpharma CEO Dr Jackie Fairley to discuss how the COVID19 pandemic could be the catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. The article highlighted Starpharma’s recent activities in response to the pandemic, including the development of a product using its existing anti-viral dendrimer SPL7013.
To read the full article, click here.Read More
Jun 29th, 2020
Starpharma today announced its SN-38 nanoparticle, DEP® irinotecan in combination with an immuno-oncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and significant survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC model.Read More
Jun 25th, 2020
The ABC’s 7:30 report interviewed Starpharma CEO Dr Jackie Fairley to discuss the importance of creating COVID-19 preventative products while the world waits for a vaccine to be developed. Dr Fairley discussed how Starparma’s patented dendrimer SPL7013 has shown significant anti-viral activity against SARS-CoV-2 (coronavirus) and how quickly a product using this ingredient could be brought to market given its approval and use in other marketed products.
Watch the full interview click here.Read More
Jun 25th, 2020
Alan Kohler recently interviewed Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report to discuss the importance of developing other methods of protection against COVID-19 while we wait for a vaccine. Jackie also discusses how Starpharma’s patented dendrimer SPL7013 is being developed for use in an antiviral nasal spray to prevent COVID-19 infection.
Watch the full interview here: https://www.abc.net.au/7.30/how-long-will-the-economy-take-to-recover/12394342Read More
Jun 23rd, 2020
Starpharma today announced that five posters featuring products based on Starpharma’s DEP® platform have been presented at the AACR (American Association for Cancer Research) Annual Meeting. The AACR Annual Meeting brings together leading cancer research and medicine from institutions all over the world and is an important forum for both raising product awareness and commercial interactions.Read More
Jun 19th, 2020
A new study using Australian data showed a causal link between female leadership and business performance. Starpharma is one of only 15 ASX300 companies to have a female CEO and Dr Jackie Fairley spoke with SBS about the importance of having senior female leaders in a corporate setting.
For the full interview click here.Read More
Jun 19th, 2020
Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the company’s first radiotherapeutic candidate, DEP® lutetium. The candidate showed highly statistically significant anticancer activity, tumour regression and 100% survival in a human prostate cancer model. The interview also covered the company’s latest VivaGel® BV launch in Central and Eastern Europe.
To watch the full interview click here.
Jun 18th, 2020
Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 18 June 2020 (US ET) as part of OTCQX’s Virtual Investor Conference for Global Mid-cap and Large-cap Companies. The conference is primarily attended by US-based retail investors, as well as advisors.
Jun 17th, 2020
Starpharma today announced results from its first radiotherapeutic candidate, DEP® lutetium. DEP® lutetium is a patented nanoparticle which incorporates the radioisotope Lutetium-177 on a DEP® dendrimer scaffold.
Jun 16th, 2020
Starpharma today announced that VivaGel® BV has been launched in Central and Eastern European (CEE) region. This launch follows European launches in Germany, UK and several other European countries.Read More
May 18th, 2020
The Canadian arm of finance news network Proactive Investors recently interviewed Starpharma CEO Dr Jackie Fairley to discuss the Company's DEP® portfolio and the recent news that Starpharma is investigating product concepts for proprietary dendrimer SPL7013 in relation to COVID-19.
Watch the full interview here: https://www.youtube.com/watch?v=jqn06bUymDw&feature=youtu.beRead More
May 14th, 2020
In this issue:
>> VivaGel® BV launched in Asia
>> Fleurstat BVgel launched in NZ
>> DEP® irinotecan phase 2 commences after positive phase 1 results
>> SPL7013 against SARS-COV-2 (coronavirus)
>> Fleurstat BVgel ranks as #1 topical BV treatment
>> Okamoto adds 11 more Asian countries to licence
>> US regulatory update
>> COVID-19: Starpharma’s operations continue with minimal disruption
>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan
>> DEP® patient case studies
>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received
>> New DEP® ADC programs
>> DEP® pipeline targets multiple high-value areas
>> Other DEP® programs
>> Outlook, recent news & events
May 11th, 2020
Finance and market news website AusBiz co-founders Kylie Merritt and David Koch interviewed Starpharma CEO Dr Jackie Fairley to discuss DEP® irinotecan moving into Phase 2 and how Starpharma is investigating product concepts for SPL7013 in the fight against COVID-19.
To watch the full interview click hereRead More
May 7th, 2020
Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP® irinotecan. The trial met its objective of evaluating safety, tolerability, pharmacokinetics and preliminary efficacy data, and identifying a recommended phase 2 dose. The trial will now transition seamlessly into phase 2, with recruitment activities underway at three sites. Two additional sites, The Beatson West of Scotland Cancer Centre (the Beatson) and the Kinghorn Cancer Centre in Sydney are also expected to commence recruitment shortly.Read More
May 5th, 2020
Starpharma has been invited to present today at the Macquarie Australia Conference. Due to COVID-19, the Macquarie Australia Conference will be a virtual conference for registered institutional investors. The event will provide international and domestic institutions with the opportunity to hear from a range of invited Australian companies over three days. Starpharma is one of a handful of companies in the pharmaceutical/biotech and healthcare industries to be presenting during the conference.Read More
Apr 22nd, 2020
US biotech publication BioWorld noted that a number of Australian biotech companies have been testing agents in the fight against COVID-19, in particular highlighting Starpharma’s SPL7013 which showed significant positive antiviral activity against the SARS-CoV-2 virus.
To read the full article, click hereRead More
Apr 16th, 2020
The Australian Financial Review interviewed Starpharma CEO Dr Jackie Fairley for an article highlighting the company’s finding that its antiviral dendrimer SPL7013 showed significant activity against coronavirus. The article noted SPL7013 is already used in existing and approved products within Starpharma’s VivaGel® portfolio.
To read the full article, click here (paywall).